Is the Preoperative Preparation of Sickle Cell Patients Optimal: Assessment of Practices and Post-operative Complications
Is the Preoperative Preparation of Sickle Cell Patients Optimal: Retrospective Assessment of Practices and Post-operative Complications in a Cohort of Children Followed at Hôpital Universitaire Des Enfants Reine Fabiola (HUDERF) and Who Have Been Managed According Local Guidelines Including Transfusion or Exchange Transfusion Before Surgery
Children with sickle cell disease systematically receive a transfusion 2 to 5 days before scheduled surgery (with the exception of minor surgeries) in order to avoid post-operative complications of which the vaso-occlusive crisis and acute thoracic syndrome are the most frequent.
This standardized preoperative protocol was established on the basis of the results of large-scale randomized studies, most of which date back over ten years, and which have demonstrated the beneficial effects of transfusion (or transfusion exchange) preoperatively. To date, several other more recent studies (but not controlled) have questioned this type of systematic management.
The purpose of this study is to review retrospectively data of sickle cell children who have undergone elective surgery at the Huderf in the last ten years and to identify the eventual complications encountered. The most common procedures in these patients are: tonsillectomy with or without associated adenoids, splenectomy and cholecystectomy.
General data on sickle cell disease (history, genotype, G6PD deficiency, biology and previous complications), pre-surgical preparation, surgery and post surgical management and complications will be collected and analyzed.
This retrospective analysis will allow an objective assessment of the current quality of care and will provide useful data to improve patient management.
調査の概要
状態
条件
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
Brussles
-
Brussels、Brussles、ベルギー、1020
- Hopital Universitaire des Enfants Reine Fabiola
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Sickle cell disease with surgery during the 2010-2019 period
Exclusion Criteria:
- None
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:回顧
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess the overall incidence of vaso-occlusive-events 1 month post surgery
時間枠:1 month after surgery
|
Vaso-occlusive-events will include Vaso Occlusive Crisis (acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)), acute chest syndrome (new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever) and hemoglobin < 6g/dl
|
1 month after surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess the incidence of Vaso Occlusive Crisis 1 month post surgery
時間枠:1 month after surgery
|
Vaso Occlusive Crisis is defined as acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)
|
1 month after surgery
|
|
To assess the incidence of Vaso Occlusive Crisis 3 months post surgery
時間枠:3 months after surgery
|
Vaso Occlusive Crisis is defined as acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)
|
3 months after surgery
|
|
To assess the incidence of Vaso Occlusive Crisis 12 months post surgery
時間枠:12 months after surgery
|
Vaso Occlusive Crisis is defined as acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)
|
12 months after surgery
|
|
To assess the incidence of Acute Chest Syndrome 1 month post surgery
時間枠:1 month after surgery
|
Acute Chest Syndrome is defined as a new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever
|
1 month after surgery
|
|
To assess the incidence of Acute Chest Syndrome 3 months post surgery
時間枠:3 months after surgery
|
Acute Chest Syndrome is defined as a new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever
|
3 months after surgery
|
|
To assess the incidence of Acute Chest Syndrome 12 months post surgery
時間枠:12 months after surgery
|
Acute Chest Syndrome is defined as a new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever
|
12 months after surgery
|
|
To assess the duration of hospitalization post-surgery
時間枠:1 month after surgery
|
number of days between surgery and day of discharge
|
1 month after surgery
|
|
To assess the incidence of Red Blood Cell (RBC) allo-immunization 1 month post surgery
時間枠:1 month after surgery
|
incidence of acute anemia with the presence of new allo-antibody(ies) against RBC
|
1 month after surgery
|
|
To assess the incidence of RBC allo-immunization 3 months post surgery
時間枠:3 months after surgery
|
incidence of acute anemia with the presence of new allo-antibody(ies) against RBC
|
3 months after surgery
|
|
To assess the incidence of RBC allo-immunization 12 months post surgery
時間枠:12 months after surgery
|
incidence of acute anemia with the presence of new allo-antibody(ies) against RBC
|
12 months after surgery
|
|
To assess the number of RBC transfusion episodes 1 month post surgery
時間枠:1 month after surgery
|
Number of RBC unit transfused
|
1 month after surgery
|
協力者と研究者
捜査官
- 主任研究者:Alina Ferster, MD、Queen Fabiola Children's University Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- P2020/Hemato/SCDPreop
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。